Drugs for hypercholesterolaemia – from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition
Anthony S Wierzbicki and Paul Grant
DOI: https://doi.org/10.7861/clinmedicine.16-4-353
Clin Med August 2016 Anthony S Wierzbicki
AGuy’s and St Thomas’ Hospitals, London, UK
Roles: consultant in metabolic medicine/chemical pathology
Paul Grant
BOCDEM, Churchill Hospital, Headington, Oxford, UK
Roles: consultant physician
Article Tools
Drugs for hypercholesterolaemia – from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition
Anthony S Wierzbicki, Paul Grant
Clinical Medicine Aug 2016, 16 (4) 353-357; DOI: 10.7861/clinmedicine.16-4-353
Citation Manager Formats
Jump to section
- Article
- ABSTRACT
- Introduction
- Novel interventions in cardiovascular disease
- Statins and cardiovascular disease
- Pro-protein convertase subtilisin kexin 9
- Intervention on PCSK9
- Antibody-based therapies
- Use in statin-intolerant populations
- Outcome of phase III studies
- Limitations of phase III trials with PCSK9 inhibitors
- The current context of LDL-C reduction therapies
- Conclusion
- Conflicts of interest
- References
- Figures & Data
- Info & Metrics
Related Articles
- No related articles found.